StreetInsider.com News Articles

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:57:00 -0400

si-local-file:///var/storage/secattach/20260708/26744382.html

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:57:00 -0400

si-local-file:///var/storage/secattach/20260708/26744382.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: Tinmouth Brian Philippe

Tue, 30 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260630/26713672.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: Tinmouth Brian Philippe

Tue, 30 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260630/26713672.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: Macdonald Guy

Tue, 30 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260630/26713641.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: Macdonald Guy

Tue, 30 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260630/26713641.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: ANIDO ARMANDO

Tue, 30 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260630/26713595.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: ANIDO ARMANDO

Tue, 30 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260630/26713595.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: HASTINGS DAVID C

Tue, 30 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260630/26713479.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: HASTINGS DAVID C

Tue, 30 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260630/26713479.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: HANHAM ANN

Tue, 30 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260630/26713438.html

Form 4 SCYNEXIS INC For: Jun 26 Filed by: HANHAM ANN

Tue, 30 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260630/26713438.html

Scynexis starts Phase 1 trial of SCY-770 for rare kidney disease

Tue, 30 Jun 2026 08:02:00 -0400

Scynexis (NASDAQ: SCYX) announced the initiation of a Phase 1 clinical study of SCY-770, an AMP-activated protein kinase (AMPK) activator being developed for Autosomal Dominant Polycystic Kidney Disease (ADPKD), according to a company press release.

The study will enroll healthy participants in a sequential design. An initial cohort will receive a single 500 mg dose of SCY-770 under fed and fasted conditions to assess food effect and pharmacokinetics. Subsequent cohorts will evaluate SCY-770 at 750 mg once daily or 500 mg twice daily, compared with placebo, over seven days. Topline data are expected in the third quarter of 2026.

Results from the

Scynexis starts Phase 1 trial of SCY-770 for rare kidney disease

Tue, 30 Jun 2026 08:02:00 -0400

Results from the

Scynexis starts Phase 1 trial of SCY-770 for rare kidney disease

Tue, 30 Jun 2026 08:02:00 -0400

Results from the

Scynexis starts Phase 1 trial of SCY-770 for rare kidney disease

Tue, 30 Jun 2026 08:02:00 -0400

Results from the

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Tue, 30 Jun 2026 08:00:00 -0400

JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator. The study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), on track for Q4 2026.